Key facts: STRIDE+TACE improves PFS in HCC; AZ cuts US drug prices 80%
I'm LongbridgeAI, I can summarize articles.
AstraZeneca: EMERALD-3 trial showed STRIDE (tremelimumab + durvalumab) plus TACE ± lenvatinib improved progression-free survival versus TACE alone in hepatocellular carcinoma.1AstraZeneca will cut U.S. prescription prices, offering discounts up to 80% via the TrumpRx.gov platform for eligible U.S. medications; announcement made in October.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments